Prolor Biotech reported positive preclinical results from an animal study of its long-acting obesity/Type II diabetes drug candidate MOD-6030. During the trial, the drug was administered to diet-induced obese mice once weekly over a 30-day period. According to Prolor, the results demonstrated efficacy in reducing weight, lowering blood glucose levels, increasing insulin sensitivity and reducing cholesterol levels as compared to a group that received placebo.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Non-Profit Launches 10M Shekel Fund For Israeli Small Businesses
December 06, 2023

Amid War, Program Helps Open US Doors For 10 Israeli Startups
December 06, 2023

Israeli Data Privacy Startup Raises $30M in Wartime
December 05, 2023

Israel Awards ‘World’s First’ License For Drone Flights
December 05, 2023
Facebook comments